

THE DEFINITION OF AVAILABILITY OF ANTIHISTAMINIC DRUGS FOR UKRAINIAN PATIENTS

Perederiy A. V., Iakovlieva L.V.

The National University of Pharmacy, Kharkiv, Ukraine

ana2971@i.ua

In recent years there is trend to a significant increase in the frequency of allergic pathology worldwide. According to the data of World Health Organization (WHO) various allergic symptoms and diseases recorded in 7-30% of cases of all diseases. According to statistics, in Ukraine approximately 1.5% of the population has been diagnosed an allergy. However, the actual figures are much higher – up to 25% of population or about 10 million people, so determining the availability of antihistaminic drugs (AHDs) for Ukrainian patients is a priority.

The aim of the study was to determine the availability AHDs for Ukrainian patients in 2014.

Materials and methods. To determine the availability of AHDs for patients were calculated ratio of the adequacy of solvency (Ca.s.) and the availability coefficient (D) of drugs in 2013-2014.

Results. In 2013 in accordance with the calculated Ca.s., weekly costs for patient treatment with AHDs were from 0.05% - 6.37% of the average wage, and in 2014 - from 0.03% to 6.73%. In 2013-2014 the trade names (TNs) AERIUS® (syrup 0.5 mg/ml vials. 60 ml, Switzerland), TELFAST (tablets 180 mg № 10 and 30 mg № 10, France) were least accessible for patients, because the costs in 2014 ranged from 5.23% to 6.73% of the average wage. Although specified by the high ratio of the adequacy of solvency AHDs were available.

The coefficients of availability (D) showed that the availability of AHDs for patients in 2014 decreased in comparison with the year 2013: only 25 TNs of 105 drugs, which were presents in the market in 2014, were available for patients, in 2013 77 TN from 121 drugs were available. In 2013 the TNs of desloratadine, and in 2014 the TNs of fexofenadine became more available.

Conclusion. The ratio of the adequacy of solvency and the coefficients of availability showed that many AHDs for the treatment of allergic diseases were not available for patients. In comparison with 2013 availability of AHDs in 2014 sharply decreased, but Ukrainian patients can afford to continue treatment with AHDs, because the maximum costs for AHDs were 6,73% of average monthly salary.